Thanks, Dan. Total revenue for the fourth quarter of fiscal 2019 decreased 29%, compared to an especially strong quarter last year. The decrease was due to decreases in both product sales and contract R&D. The decrease in product sales was primarily due to an expected decrease in custom anti-tamper product sales, which we discussed in our January call, and a decrease in products for medical devices. Anti-tamper and medical market timing can fluctuate. We have some visibility into improved anti-tamper sales this quarter. We currently believe anti-tamper sales will pick up this quarter, the quarter ending June 30. Gross margin decreased to 77% from 81%, due to revenue mix. Total expenses decreased 2% for the fourth quarter from the prior year, due to a 34% decrease in SG&A, partially offset by a 12% increase in R&D. Dan will discuss R&D in a few minutes. Interest income for the fourth quarter increased 14%, due to an increase in the average interest rates on our marketable securities, partially offset by a decrease in our securities as we used some of our maturing securities to fund dividends. Our effective tax rate was 18%, compared to 30% in the prior year quarter. The decreased tax rate was due to the full effects of tax reform in the past year. After-tax net income for the quarter was $2.86 million or $0.59 per diluted share, compared to $3.88 million or $0.80 last year. For the fiscal year, total revenue decreased 11%, due to a 7% decrease in product sales and a 54% decrease in contract R&D. The decrease in product sales for the year was primarily due to a decrease in custom anti-tamper product sales, and the decrease in contract R&D was due to the completion of certain contracts. As of March 31, we had $355,000 of contract research and development backlog we believe to be firm. We expect that backlog to be filled this fiscal year. Gross margin increased to 80% for the year from 79% for the prior year, due to a more profitable revenue mix. Expenses in fiscal 2019 increased 4%, due to an 11% increase in R&D, partially offset by a 15% decrease in SG&A. R&D expense was 16% of revenue, which is a substantial investment in our future. In addition to company-sponsored R&D, which is an expense item, we have customer-sponsored R&D activities included in cost of sales. The high level of R&D activity has yielded new products with more on the way. Interest income increased 15%, due to an increase in the average interest rates on our marketable securities, partially offset by a decrease in our securities. Our fiscal year tax rate decreased to 18% from 30% in the prior year, due to the impact of tax reform. As Dan said, net income for the fiscal year increased 4% to a record $14.5 million or $2.99 per diluted share, compared to $13.9 million or $2.87 per share last year. Net margin increased to 55% from 47%. Comprehensive income, which includes unrealized gains and losses, increased 18% to $15.4 million, compared to $13 million last year as the strong bond market increased the value of many of our marketable securities. Fixed asset purchases were a modest $68,000 in the most recent year, compared to $605,000 last year. We paid $4 per share in dividends in the past year, which brought the total since we started paying dividends in 2015 to more than $87 million. In addition, we announced today that our Board declared another quarterly dividend of $1 per share payable May 31 to shareholders of record as of May 13. That will bring our total dividends to over $90 million. Now, I'll turn it over to Dan to cover the business. Dan?